Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
89
resultados
Última actualización
18/03/2026 [07:14:00]
Resultados 75 a 89 de 89
Resumen de: US20260022111A1
Provided herein are compounds having a structure of formula (I) or formula (II):or a pharmaceutically acceptable salt, solvate, or hydrate thereof, useful in treating or preventing coronavirus infection. In some embodiments, the coronavirus infection is COVID-19 (SARS-COV-19). Also provided are compositions comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus infection.
Resumen de: AU2024280139A1
The present invention relates to an immunogenic composition comprising a recombinant peptide and protein, wherein the recombinant peptide and protein comprise a coronavirus antigen and immunogen, for example, a chimeric antigen and immunogen of an S protein peptide or a fragment, variant or mutant sequence thereof of SARS-CoV-2 Hu-1, SARS-CoV-2 Omicron (BA.5 and/or XBB.1.5) variant, and/or other variants. The immunogenic composition comprises a secreted fusion protein, which comprises a soluble coronavirus antigen, wherein the soluble coronavirus antigen protein is linked, by means of in-frame fusion, to a C-terminal moiety of a collagen capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. The immunogenic composition can be used for generating an immune response, and can be used in a vaccine composition. Further provided are methods for producing a recombinant peptide and protein, methods for prevention, treatment and/or diagnosis, and a related kit.
Resumen de: AU2024303786A1
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
Resumen de: AU2024308469A1
Disclosed are glycanic compounds and their use for treating or inhibiting the development of a viral infection in a subject, especially a coronavirus infection, such as a SARS-CoV-2 infection, or for treating conditions associated with viral infections, such as an acute inflammatory condition, cytokine release syndrome (CRS) or a cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).
Resumen de: AU2025283673A1
Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of SARS-CoV-2 nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding formulations, reaction mixtures, and kits and related methods for preparing aqueous reaction mixtures from dried formulations. ec e c
Resumen de: WO2026016695A1
Disclosed is use of coronavirus SL5s as targets in the preparation of a drug for preventing and treating coronavirus infection. The drug target coronavirus SL5s described in the present invention are the stem-loops 5 of the 5'UTR regions of coronaviruses, which participate in regulating viral mRNA translation. Further disclosed is an inhibitor of the SL5s of 7 human infectious coronaviruses, i.e., an antisense oligonucleotide specifically targeting the SL5s for inhibiting coronavirus infection. Experiments have demonstrated that the application of the antisense oligonucleotide specifically targeting the coronavirus SL5s in vitro can significantly inhibit the translation levels of the coronavirus mRNAs. The coronavirus SL5s described in the present invention can be used as drug targets to screen for candidate drugs for inhibiting coronavirus mRNA translation, showing great significance for the development of anti-coronavirus drugs and the prevention and treatment of coronaviruses in the future.
Resumen de: WO2026018060A1
The present invention in general relates to a pharmaceutical formulation, specifically a dry powder inhalation formulation for treatment of Corona virus disease-19 (COVID-19). The formulation comprises of combination of an antiviral and a corticosteroid. The invention further describes the method of preparation of the dry powder inhalation formulation.
Resumen de: WO2026019338A1
The invention relates to organic chemistry, pharmacology and medicine and concerns novel antiviral peptides. The claimed peptides are characterized by a high level of antiviral activity and show promise for use in the treatment of infectious diseases caused by a viral infection, inter alia, diseases caused by SARS-CoV-2 such as, for example, a simple infection (such as a fever, a cough and/or a sore throat), pneumonia, acute or severe respiratory infection, hypoxic respiratory failure, acute respiratory distress syndrome, sepsis or septic shock and, in particular, COVID-19.
Resumen de: WO2026018922A1
The purpose of the present disclosure is to provide highly versatile, ready-to-deliver allogenic T cells for novel coronavirus infection, and a production method therefor. The present invention provides: a method for producing a cell population for the treatment and/or prevention of SARS-CoV-2 infection and including T cells or precursor T cells that express a human T cell receptor (TCR) specific to SARS-CoV-2, said method comprising a step for causing the expression of one or more human TCRs specific to SARS-CoV-2 in T cells or precursor T cells in vitro; and a cell population for the treatment and/or prevention of SARS-CoV-2 infection and produced via said method, said cell population comprising allogenically derived T cells or precursor T cells.
Resumen de: EP4682160A1
The present invention relates to a protein and a vaccine against infections by a SARS-CoV-2 Omicron variant XBB and subvariants thereof, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic agents against the infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof, the present invention provides proteins and vaccines against infections by the variants, the vaccines are designed based on the full-length S protein, the receptor-binding domain (RBD) sequence and optimized sequences of SARS-CoV-2 Omicron variant XBB and subvariant XBB.1.5, thereof, which are are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof.
Resumen de: EP4682890A2
A messenger RNA (mRNA) vaccine has emerged as a promising direction to combat the COVID-19 pandemic. This requires an mRNA sequence that is stable and highly productive in protein expression, features to benefit from greater mRNA secondary structure folding stability and optimal codon usage. Sequence design remains challenging due to the exponentially many synonymous mRNA sequences encoding the same protein. The present disclosure presents embodiments of a linear-time approximation (LinearDesign) reducing the design to an intersection between a Stochastic Context Free Grammar (SCFG) and a Deterministic Finite Automaton (DFA). Embodiments of the LinearDesign may implement an mRNA sequence design using much reduced time with very limited loss. Various methodologies, e.g., finding alternative sequences based on k-best parsing or directly incorporating codon optimality, are presented for incorporating the codon optimality into the design. Embodiments of the LinearDesign may provide efficient computational tools to speed up and improve mRNA vaccine development.
Resumen de: CN121360172A
The invention belongs to the technical field of traditional Chinese medicine (Tibetan medicine), and particularly relates to a Tibetan medicine composition for treating new coronavirus infection and application of the Tibetan medicine composition. The invention discloses a Tibetan medicine composition for treating new coronavirus infection and application of the Tibetan medicine composition. The composition is prepared from the following components in parts by weight: 100 to 700 parts of fructus chebulae, 10 to 80 parts of radix aconiti lateralis, 10 to 60 parts of radix aucklandiae, 50 to 600 parts of rhizoma acori calami, 10 to 50 parts of Muslim myrrh, 0.01 to 50 parts of calculus bovis factitius and 0.01 to 50 parts of artificial musk. The composition can inhibit the mRNA expression of the N gene and the ORF1ab gene after the SARS-CoV-2 virus infects the Vero cell, so that the treatment on the novel coronavirus infection is realized.
Resumen de: CN121360228A
The invention discloses application of coronavirus SL5 as a target spot in preparation of a medicine for preventing and treating coronavirus infection. The drug target coronavirus SL5 is a No.5 stem loop of a 5 'UTR region of the coronavirus and participates in regulation and control of virus mRNA translation. The invention further discloses seven inhibitors capable of infecting human coronavirus SL5, namely the antisense oligonucleotides specifically targeting SL5 are used for inhibiting coronavirus infection. Experiments prove that the translation level of coronavirus mRNA can be remarkably inhibited by applying the antisense oligonucleotide specifically targeting the coronavirus SL5 in vitro. The coronavirus SL5 provided by the invention can be used as a drug target for screening candidate drugs for inhibiting the translation of coronavirus mRNA, and is of great significance to the development, prevention and treatment of anti-coronavirus drugs in the future.
Nº publicación: CN121362139A 20/01/2026
Solicitante:
HENAN NORMAL UNIV
\u6CB3\u5357\u5E08\u8303\u5927\u5B66
Resumen de: CN121362139A
The invention discloses a brominated aniline type main protease covalent inhibitor and a preparation method and anti-coronavirus medical application thereof, and the brominated aniline type main protease covalent inhibitor comprises a compound shown as a formula I or pharmaceutically acceptable salt or deuterated substance of the compound, the structural formula of the compound shown in the formula I is shown in the specification. The invention also specifically discloses a preparation method of the brominated aniline type main protease covalent inhibitor and application of the brominated aniline type main protease covalent inhibitor in anti-coronavirus medicine. According to the invention, a series of bromo-aniline main protease covalent inhibitors are synthesized for the first time, and the bromo-aniline main protease covalent inhibitors or pharmaceutically acceptable salts or deuterated substances thereof can be used for preparing drugs for preventing or treating virus infectious diseases such as SARS-CoV-2, SARS-CoV or/and MERS-CoV and the like.
BOPI
Sede Electrónica
